The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review
- PMID: 34673334
- DOI: 10.1016/j.intimp.2021.108220
The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review
Abstract
Background: Hepatocellular carcinoma (HCC) is the most common liver neoplasm with high morbidity and mortality. Tumor immunotherapy might be promising adjuvant therapy for HCC after surgery. To better develop HCC immunotherapy, comprehensive understanding of cell-cell interactions between immune effector cells and HCC cells remains crucial.
Aim: To review the existing studies to summarize the cell-cell interactions between major immune effector cells and HCC cells providing new data for HCC immunotherapy.
Methods: A systematic review was conducted by searching PubMed database covering all papers published in recent five years up to January 2020. The guidelines of the preferred reporting items for systematic reviews were firmly followed.
Results: There are 9 studies researching the interactions between CD8+ T lymphocytes and HCC cells and 22 studies researching that between natural killer (NK) cells and HCC cells. Among the 9 studies, 6 studies reported that CD8+ T lymphocytes showed cytotoxicity towards HCC cells while 3 studies found CD8+ T lymphocytes were impaired by HCC cells. Among the 22 studies, 20 studies presented that NK cells could inhibit HCC cells. Two studies were found to report NK cell dysfunction in HCC.
Conclusion: Based on the systematic analysis, we concluded that CD8+ T lymphocytes and NK cells can inhibit HCC cells. While in turn, HCC cells can also result in the dysfunction of those effector cells through various mechanisms. Organoids and direct contact cell co-culture with primary HCC cells and TILs should be the most innovative way to investigate the interactions and develop novel immunotherapy.
Keywords: CD8(+) T lymphocytes; Cytotoxicity; Dysfunction; Hepatocellular carcinoma; Natural Killer cells.
Copyright © 2021 Elsevier B.V. All rights reserved.
Similar articles
-
Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade.Front Immunol. 2021 Apr 30;12:643310. doi: 10.3389/fimmu.2021.643310. eCollection 2021. Front Immunol. 2021. PMID: 33995362 Free PMC article. Review.
-
Strategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma.Front Immunol. 2021 Nov 26;12:783236. doi: 10.3389/fimmu.2021.783236. eCollection 2021. Front Immunol. 2021. PMID: 34899747 Free PMC article. Review.
-
Immune microenvironment and immunotherapy in hepatocellular carcinoma: mechanisms and advances.Front Immunol. 2025 Apr 2;16:1581098. doi: 10.3389/fimmu.2025.1581098. eCollection 2025. Front Immunol. 2025. PMID: 40242773 Free PMC article. Review.
-
Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.Transplantation. 2006 Dec 27;82(12):1712-9. doi: 10.1097/01.tp.0000250935.41034.2d. Transplantation. 2006. PMID: 17198265
-
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.Int J Mol Sci. 2021 May 28;22(11):5801. doi: 10.3390/ijms22115801. Int J Mol Sci. 2021. PMID: 34071550 Free PMC article. Review.
Cited by
-
Hepatocellular-Carcinoma-Derived Organoids: Innovation in Cancer Research.Cells. 2024 Oct 18;13(20):1726. doi: 10.3390/cells13201726. Cells. 2024. PMID: 39451244 Free PMC article. Review.
-
EIF2S2 is a novel independent prognostic biomarker and correlated with immune infiltrates in hepatocellular carcinoma.Front Genet. 2022 Oct 5;13:992343. doi: 10.3389/fgene.2022.992343. eCollection 2022. Front Genet. 2022. PMID: 36276981 Free PMC article.
-
PES1 is a biomarker of head and neck squamous cell carcinoma and is associated with the tumor microenvironment.Cancer Med. 2023 Jun;12(11):12622-12638. doi: 10.1002/cam4.5948. Epub 2023 Apr 19. Cancer Med. 2023. PMID: 37076985 Free PMC article.
-
Mesenchymal stem cells-based therapy in liver diseases.Mol Biomed. 2022 Jul 27;3(1):23. doi: 10.1186/s43556-022-00088-x. Mol Biomed. 2022. PMID: 35895169 Free PMC article. Review.
-
A novel fatty acid metabolism-related gene prognostic signature and candidate drugs for patients with hepatocellular carcinoma.PeerJ. 2023 Jan 6;11:e14622. doi: 10.7717/peerj.14622. eCollection 2023. PeerJ. 2023. PMID: 36632140 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials